drugset / Trial / NCT06982859

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

NCT06982859

Phase 1 Active not recruiting 95 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.

Timeline

Start
2025-06-02
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Retatrutide Protein / enzyme biologic Subcutaneous
Comparator Semaglutide Peptide Subcutaneous